期刊文献+

急性冠脉综合征单核细胞PPARδ表达及其与血清MMP-9和TIMP-1的相关性

PPARδ Expression in Acute Coronary Syndromes Monocyte and Its Correlation with MMP-9 and TIMP-1 in Serum
原文传递
导出
摘要 目的:观察急性冠脉综合征(ACS)患者外周血单核细胞中过氧化物酶体增殖激活受体δ(PPARδ)的表达及其与基质金属蛋白酶-9(MMP-9)、组织金属蛋白酶抑制物-1(TIMP-1)的相关性。方法:纳入52例ACS患者和46例健康对照者,分离其外周血单核细胞,采用逆转录聚合酶链反应(RT-PCR)方法检测PPARδ的表达;采用酶联免疫吸附试验检测血清MMP-9和TIMP-1的水平。结果:ACS患者外周血单核细胞中PPARδ的表达水平显著低于健康对照组(p<0.01);ACS患者血清MMP-9水平高于健康对照组(p<0.01),而TIMP-1水平低于健康对照组(p<0.01);PPARδ表达水平与MMP-9呈负相关(r=-0.421,p<0.05),而与TIMP-1呈正相关(r=0.531,p<0.05)。结论:PPARδ可能在ACS的发病中具有重要作用。 Objectives:To investigate the level of peroxisome proliferator-activated receptors δ(PPARδ) expression in peripheral blood monocytes from patients with acute coronary syndrome(ACS) and to analysis the correlation among levels of PPARδ,matrix metalloproteinase-9(MMP-9) and Tissue-Inhibitor of Metalloproteinase-1(TIMP-1).Methods:Peripheral blood monocytes were collected from 52 patients with ACS and 46 healthy controls.The PPARδ expression was detected by RT-PCR,while the serum level of MMP-9 and TIMP-1 were measured by ELISA assay.Results:The PPARδ expression level was markedly reduced in peripheral blood monocytes from patients with ACS compared with healthy controls(p0.01).The serum MMP-9 level was significant higher while the TIMP-1 level was obvious lower in patients with ACS than controls(both p0.01).Furthermore,the PPAR δ expression level was negatively correlated to MMP-9 level(r=-0.421,p0.05) and positively related to TIMP-1 level(r=0.531,p0.05).Conclusion:The PPARδ might play a pivotal role in the pathogenesis of ACS.
出处 《现代生物医学进展》 CAS 2010年第1期115-117,160,共4页 Progress in Modern Biomedicine
关键词 冠状动脉疾病 单核细胞 基因表达 粘附分子 Aoronary artery disease Monocytes Gene expression Adhesion molecule
  • 相关文献

参考文献14

  • 1Robinson E, Grieve DJ. Significance ofperoxisome proliferator-activated receptors in the cardiovascular system in health and disease [J]. Pharmacol Ther, 2009,122(3):246-263.
  • 2Stienstra R, Duval C, Muller M, et al. PPARs, Obesity, and Inflammation[J]. PPAR Res, 2007,2007,95974.
  • 3Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature[J]. Circulation, 1979,59(3):607-609.
  • 4Ross R. Atherosclerosis--an inflammatory disease [J]. N Engl J Med, 1999,340(2): 115-126.
  • 5Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat[J]. Cardiovasc Res, 2000,46(2):307-315.
  • 6Shu J, Ren N, Du JB, et al. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome[J]. Scand Cardiovasc J, 2007,41 (3): 149-154.
  • 7Blankenberg S, Rupprecht H J, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease [J]. Circulation, 2003,107 (12): 1579-1585.
  • 8Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and bioclaemistry[J]. Circ Res, 2003,92(8):827-839.
  • 9Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart fail'ure?[J] Circ Res, 2001,89(3):201-210.
  • 10Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation[J]. Inflamm Res, 2000,49(10):497-505.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部